FDA Speeds Up Generic Drug Approvals with Fewer Clinical Trials
Published Date: 11/20/2025
Notice
Summary
The FDA just dropped new draft guidance to help drug makers show their biosimilar products work like the original ones without always needing extra big clinical studies. This update affects companies developing biosimilar drugs, aiming to speed up approvals and save money by cutting unnecessary tests. Comments on this draft are open until January 20, 2026, so industry folks should jump in now to shape the final rules!
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Draft Guidance Released for Biosimilars
The FDA published a draft guidance titled "Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies." The guidance describes considerations for when comparative clinical studies with efficacy endpoints (CES) are needed to support a marketing application under section 351(k) of the Public Health Service Act.
Analytical Tests May Replace Some Clinical Trials
FDA states a comparative analytical assessment is generally more sensitive than a comparative efficacy study (CES) for detecting differences between a proposed biosimilar and its reference product. The draft guidance explains scientific considerations for determining when a CES may not be necessary to support a demonstration of biosimilarity.
Agency Seeks Comments on Cost Savings
FDA requests public comments on the draft guidance and specifically asks for comments on costs or cost savings the guidance may generate, including potential cost savings for biosimilar development programs that use a streamlined approach. Submit electronic or written comments by January 20, 2026 for consideration as the Agency develops the final guidance.
Guidance Is Non‑Binding; Alternatives Allowed
FDA states the draft guidance does not establish any rights and is not binding on FDA or the public. You may use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-20379 — Competitive Postal Products
The Postal Service is changing prices for some international mail going to French Guiana, Guadeloupe, Martinique, and Reunion starting January 18, 2026. This affects both regular and competitive mail products. The Postal Regulatory Commission is asking the public to share their thoughts by December 5, 2025, to make sure these changes are fair and clear.
Next: 2025-20381 — Meeting of the U.S. Naval Academy Board of Visitors
The U.S. Naval Academy Board of Visitors will meet on December 1, 2025, to check on how things are going with student life, teaching, equipment, and money at the Academy. The first part of the meeting is open to the public, but the last hour is private to discuss sensitive student discipline issues. This meeting helps keep the Academy running smoothly and supports the midshipmen’s success.